tiprankstipranks
Centessa Pharmaceuticals (CNTA)
NASDAQ:CNTA
US Market
Want to see CNTA full AI Analyst Report?

Centessa Pharmaceuticals (CNTA) Stock Forecast & Price Target

231 Followers
See the Price Targets and Ratings of:

CNTA Analyst Ratings

Hold
10Ratings
Hold
1 Buy
9 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Centessa
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CNTA Stock 12 Month Forecast

Average Price Target

$42.40
▲(6.91% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Centessa Pharmaceuticals in the last 3 months. The average price target is $42.40 with a high forecast of $47.00 and a low forecast of $38.00. The average price target represents a 6.91% change from the last price of $39.66.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","21":"$21","30":"$30","39":"$39","48":"$48"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$47.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,21,30,39,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.86,40.40923076923077,40.958461538461535,41.50769230769231,42.05692307692308,42.606153846153845,43.15538461538461,43.70461538461539,44.253846153846155,44.80307692307692,45.35230769230769,45.901538461538465,46.45076923076923,{"y":47,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.86,40.05538461538462,40.25076923076923,40.44615384615385,40.64153846153846,40.83692307692308,41.03230769230769,41.22769230769231,41.42307692307692,41.61846153846154,41.81384615384615,42.00923076923077,42.20461538461538,{"y":42.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.86,39.716923076923074,39.573846153846155,39.43076923076923,39.28769230769231,39.144615384615385,39.00153846153846,38.85846153846154,38.715384615384615,38.57230769230769,38.42923076923077,38.286153846153844,38.143076923076926,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.17,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.81,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.27,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.47,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.19,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.51,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.86,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$47.00Average Price Target$42.40Lowest Price Target$38.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on CNTA
Evercore ISI
Evercore ISI
Buy
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX), Centessa Pharmaceuticals (NASDAQ: CNTA) and Perspective Therapeutics (NYSE MKT: CATX)
Wells Fargo Analyst forecast on CNTA
Wells Fargo
Wells Fargo
$42
Hold
5.90%
Upside
Downgraded
04/20/26
Centessa downgraded to Equal Weight from Overweight at Wells FargoCentessa downgraded to Equal Weight from Overweight at Wells Fargo
Truist Financial Analyst forecast on CNTA
Truist Financial
Truist Financial
$38
Hold
-4.19%
Downside
Downgraded
04/12/26
Centessa downgraded to Hold from Buy at TruistCentessa downgraded to Hold from Buy at Truist
Leerink Partners Analyst forecast on CNTA
Leerink Partners
Leerink Partners
$40
Hold
0.86%
Upside
Downgraded
04/01/26
Centessa downgraded to Market Perform from Outperform at LeerinkCentessa downgraded to Market Perform from Outperform at Leerink
Guggenheim
Hold
Downgraded
04/01/26
Centessa downgraded to Neutral from Buy at GuggenheimCentessa downgraded to Neutral from Buy at Guggenheim
LifeSci Capital Analyst forecast on CNTA
LifeSci Capital
LifeSci Capital
Hold
Downgraded
04/01/26
Centessa downgraded to Market Perform from Outperform at LifeSci CapitalCentessa downgraded to Market Perform from Outperform at LifeSci Capital
Needham Analyst forecast on CNTA
Needham
Needham
Hold
Downgraded
03/31/26
Centessa downgraded to Hold from Buy at NeedhamCentessa downgraded to Hold from Buy at Needham
Wolfe Research Analyst forecast on CNTA
Wolfe Research
Wolfe Research
Hold
Downgraded
03/31/26
Analysts Conflicted on These Healthcare Names: Centessa Pharmaceuticals (NASDAQ: CNTA), Cabaletta Bio (NASDAQ: CABA) and Inventiva (NASDAQ: IVA)
Stephens
$35$47
Hold
18.51%
Upside
Downgraded
03/31/26
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (NASDAQ: CNTA), UnitedHealth (NYSE: UNH) and Adagio Medical Holdings (NASDAQ: ADGM)
B. Riley Securities Analyst forecast on CNTA
B. Riley Securities
B. Riley Securities
$45
Hold
13.46%
Upside
Downgraded
03/31/26
Centessa downgraded to Neutral from Buy at B. RileyCentessa downgraded to Neutral from Buy at B. Riley
Piper Sandler Analyst forecast on CNTA
Piper Sandler
Piper Sandler
$38
Buy
-4.19%
Downside
Reiterated
01/16/26
Analysts Are Bullish on Top Healthcare Stocks: Zymeworks (ZYME), Centessa Pharmaceuticals (CNTA)
Oppenheimer Analyst forecast on CNTA
Oppenheimer
Oppenheimer
$62
Buy
56.33%
Upside
Reiterated
01/15/26
Analysts Are Bullish on Top Healthcare Stocks: Centessa Pharmaceuticals (CNTA), Ufp Technologies (UFPT)
Jefferies Analyst forecast on CNTA
Jefferies
Jefferies
$27$30
Buy
-24.36%
Downside
Reiterated
11/13/25
Centessa Pharmaceuticals (CNTA) Gets a Buy from Jefferies
Morgan Stanley Analyst forecast on CNTA
Morgan Stanley
Morgan Stanley
$27
Buy
-31.92%
Downside
Reiterated
11/12/25
Centessa Pharmaceuticals: Promising Market Position with ORX750's Superior Efficacy and Potential
TD Cowen Analyst forecast on CNTA
TD Cowen
TD Cowen
Buy
Reiterated
11/12/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on CNTA
Evercore ISI
Evercore ISI
Buy
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX), Centessa Pharmaceuticals (NASDAQ: CNTA) and Perspective Therapeutics (NYSE MKT: CATX)
Wells Fargo Analyst forecast on CNTA
Wells Fargo
Wells Fargo
$42
Hold
5.90%
Upside
Downgraded
04/20/26
Centessa downgraded to Equal Weight from Overweight at Wells FargoCentessa downgraded to Equal Weight from Overweight at Wells Fargo
Truist Financial Analyst forecast on CNTA
Truist Financial
Truist Financial
$38
Hold
-4.19%
Downside
Downgraded
04/12/26
Centessa downgraded to Hold from Buy at TruistCentessa downgraded to Hold from Buy at Truist
Leerink Partners Analyst forecast on CNTA
Leerink Partners
Leerink Partners
$40
Hold
0.86%
Upside
Downgraded
04/01/26
Centessa downgraded to Market Perform from Outperform at LeerinkCentessa downgraded to Market Perform from Outperform at Leerink
Guggenheim
Hold
Downgraded
04/01/26
Centessa downgraded to Neutral from Buy at GuggenheimCentessa downgraded to Neutral from Buy at Guggenheim
LifeSci Capital Analyst forecast on CNTA
LifeSci Capital
LifeSci Capital
Hold
Downgraded
04/01/26
Centessa downgraded to Market Perform from Outperform at LifeSci CapitalCentessa downgraded to Market Perform from Outperform at LifeSci Capital
Needham Analyst forecast on CNTA
Needham
Needham
Hold
Downgraded
03/31/26
Centessa downgraded to Hold from Buy at NeedhamCentessa downgraded to Hold from Buy at Needham
Wolfe Research Analyst forecast on CNTA
Wolfe Research
Wolfe Research
Hold
Downgraded
03/31/26
Analysts Conflicted on These Healthcare Names: Centessa Pharmaceuticals (NASDAQ: CNTA), Cabaletta Bio (NASDAQ: CABA) and Inventiva (NASDAQ: IVA)
Stephens
$35$47
Hold
18.51%
Upside
Downgraded
03/31/26
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (NASDAQ: CNTA), UnitedHealth (NYSE: UNH) and Adagio Medical Holdings (NASDAQ: ADGM)
B. Riley Securities Analyst forecast on CNTA
B. Riley Securities
B. Riley Securities
$45
Hold
13.46%
Upside
Downgraded
03/31/26
Centessa downgraded to Neutral from Buy at B. RileyCentessa downgraded to Neutral from Buy at B. Riley
Piper Sandler Analyst forecast on CNTA
Piper Sandler
Piper Sandler
$38
Buy
-4.19%
Downside
Reiterated
01/16/26
Analysts Are Bullish on Top Healthcare Stocks: Zymeworks (ZYME), Centessa Pharmaceuticals (CNTA)
Oppenheimer Analyst forecast on CNTA
Oppenheimer
Oppenheimer
$62
Buy
56.33%
Upside
Reiterated
01/15/26
Analysts Are Bullish on Top Healthcare Stocks: Centessa Pharmaceuticals (CNTA), Ufp Technologies (UFPT)
Jefferies Analyst forecast on CNTA
Jefferies
Jefferies
$27$30
Buy
-24.36%
Downside
Reiterated
11/13/25
Centessa Pharmaceuticals (CNTA) Gets a Buy from Jefferies
Morgan Stanley Analyst forecast on CNTA
Morgan Stanley
Morgan Stanley
$27
Buy
-31.92%
Downside
Reiterated
11/12/25
Centessa Pharmaceuticals: Promising Market Position with ORX750's Superior Efficacy and Potential
TD Cowen Analyst forecast on CNTA
TD Cowen
TD Cowen
Buy
Reiterated
11/12/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Centessa Pharmaceuticals

3 Months
xxx
Success Rate
5/6 ratings generated profit
83%
Average Return
+30.68%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +30.68% per trade.
1 Year
Biren AminPiper Sandler
Success Rate
6/6 ratings generated profit
100%
Average Return
+149.62%
Copying Biren Amin's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +149.62% per trade.
2 Years
xxx
Success Rate
23/23 ratings generated profit
100%
Average Return
+184.87%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +184.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CNTA Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
10
13
8
7
2
Buy
14
13
6
2
1
Hold
0
0
0
5
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
26
14
14
13
In the current month, CNTA has received 3 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. CNTA average Analyst price target in the past 3 months is 42.40.
Each month's total comprises the sum of three months' worth of ratings.

CNTA Financial Forecast

CNTA Earnings Forecast

Next quarter’s earnings estimate for CNTA is -$0.38 with a range of -$0.51 to -$0.29. The previous quarter’s EPS was -$0.41. CNTA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CNTA has Performed in-line its overall industry.
Next quarter’s earnings estimate for CNTA is -$0.38 with a range of -$0.51 to -$0.29. The previous quarter’s EPS was -$0.41. CNTA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CNTA has Performed in-line its overall industry.

CNTA Sales Forecast

Next quarter’s sales forecast for CNTA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CNTA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CNTA has Performed in-line its overall industry.
Next quarter’s sales forecast for CNTA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CNTA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CNTA has Performed in-line its overall industry.

CNTA Stock Forecast FAQ

What is CNTA’s average 12-month price target, according to analysts?
Based on analyst ratings, Centessa Pharmaceuticals’s 12-month average price target is 42.40.
    What is CNTA’s upside potential, based on the analysts’ average price target?
    Centessa Pharmaceuticals has 6.91% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CNTA a Buy, Sell or Hold?
          Centessa Pharmaceuticals has a consensus rating of Hold which is based on 1 buy ratings, 9 hold ratings and 0 sell ratings.
            What is Centessa Pharmaceuticals’s price target?
            The average price target for Centessa Pharmaceuticals is 42.40. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $47.00 ,the lowest forecast is $38.00. The average price target represents 6.91% Increase from the current price of $39.66.
              What do analysts say about Centessa Pharmaceuticals?
              Centessa Pharmaceuticals’s analyst rating consensus is a Hold. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of CNTA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.